Core Viewpoint - Medtronic plc (NYSE:MDT) is recognized as one of the 15 Best Wide Moat Dividend Stocks to invest in, highlighting its strong market position and dividend potential [1]. Group 1: Acquisition Details - Medtronic announced plans to acquire CathWorks for up to $585 million, aimed at enhancing its heart devices portfolio with a new diagnostic tool for assessing coronary artery disease [2]. - The acquisition provides access to the CathWorks FFRangio System, which evaluates coronary artery disease non-invasively, addressing a common heart issue caused by plaque buildup [3]. - The deal builds on a strategic partnership established with CathWorks in 2022, indicating a well-planned progression rather than a sudden shift [5]. Group 2: Financial Impact - Heart devices account for nearly 40% of Medtronic's total revenue, which includes pacemakers and the rapidly growing Pulsed Field Ablation business, making the addition of a diagnostic capability a natural fit [4]. - The transaction is pending clearance from the U.S. Federal Trade Commission, with expectations for closure by the end of fiscal 2026 [5]. Group 3: Analyst Insights - UBS raised its price target for Medtronic to $104 from $103 while maintaining a Neutral rating, reflecting a cautious but optimistic outlook on the stock [2][8].